Randomization and masking
infections
INFECTIONS
Patients were randomly assigned in a 1:1 ratio to either eculizumab plus care as usual (intervention group) or care as usual alone (control group). Randomization occurred by a centralized secured website based on a computer-generated block randomization scheme (block size of one or two). No stratification factors were used. Patients and/or their legal representatives, treating physicians, and the research team were informed about the treatment allocation. Research team members who assessed the primary outcome and serological parameters (lab technicians), modified Rankin Scale (mRS) score (research nurse), and infections (HFW, AHWB) were masked to treatment allocation.